HB Wealth Management
CTMX icon

HB Wealth Management’s CytomX Therapeutics CTMX Stock Holding History

HB Wealth Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$235K – 1736
2026
Q1 		$235K Buy
50,000
+25,000
+100% +$127K ﹤0.01% 1354
2025
Q4 		$106K Buy
+25,000
New +$95K ﹤0.01% 1364

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

HB Wealth Management's CTMX Position: Q2 2026 in Review

HB Wealth Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 50,000 shares — an estimated $235K sold.

HB Wealth Management first reported a position in CTMX in Q4 2025 and held it in 2 quarters. The position peaked at $235K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • HB Wealth Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HB Wealth Management sold 50,000 CytomX Therapeutics shares in Q2 2026, an estimated $235K.
  • HB Wealth Management first reported a position in CytomX Therapeutics in Q4 2025 and held it in 2 quarters.
  • HB Wealth Management's CytomX Therapeutics position peaked at $235K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.